In this webinar, we will discuss how advances in bioanalytical assays and technologies have improved immunoassay performance, closing the gap in assay drawbacks for cell and gene therapy manufacturing.
Examples from Gyrolab® microfluidic, CD-based immunoassay platform will be presented demonstrating AAV titer, LV titer, and bioprocessing HEK 293 host cell protein impurity analysis improvements.
Through the panel discussion, attendees will learn about:
- Bioanalytical bottlenecks in viral vector manufacturing and bioprocessing
- Impact of increased regulatory demands, long assay times and large sample consumption on vector characterization
- Strategies for addressing immunoassay speed, accuracy, and sample volumes
- Performance of microfluidic-based immunoassays for LV and AAV titer and impurity analysis
